$KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Nello Mainolfi
CEO
208
Employees
$113.51
Current Price
$6.50B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 4 | 28 | $26,757,589.88 | 237,148 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 135 | $359,211,360.87 | 3,305,761 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 5 | 144 | $380,235,793.56 | 3,537,629 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 7 | 152 | $381,870,083.10 | 3,557,813 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 7 | 170 | $387,335,381.62 | 3,621,769 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Apr 15, 2026 | Chadwick Jeremy G Chief Operating Officer | Sale | 1,300 | $90.00 | $117,000.00 | View Details |
| Apr 14, 2026 | Chadwick Jeremy G Chief Operating Officer | Sale | 5,251 | $90.00 | $472,598.40 | View Details |
| Apr 14, 2026 | Booth Bruce Director | Sale | 4,159 | $89.97 | $374,185.23 | View Details |
| Apr 15, 2026 | Booth Bruce Director | Sale | 2,200 | $89.95 | $197,890.00 | View Details |
| Apr 15, 2026 | Booth Bruce Director | Sale | 2,750 | $90.10 | $247,775.00 | View Details |
| Apr 15, 2026 | Booth Bruce Director | Sale | 385 | $90.10 | $34,688.50 | View Details |
| Apr 9, 2026 | Goodman Noah Chief Business Officer | Sale | 2,670 | $87.11 | $232,586.10 | View Details |
| Apr 10, 2026 | Goodman Noah Chief Business Officer | Sale | 2,000 | $87.35 | $174,700.00 | View Details |
| Apr 9, 2026 | Goodman Noah Chief Business Officer | Sale | 3,094 | $86.62 | $267,996.09 | View Details |
| Apr 9, 2026 | Goodman Noah Chief Business Officer | Sale | 2,500 | $89.00 | $222,500.00 | View Details |
93 more transactions available โ create a free account to see 12 months of history | ||||||
Showing 161โ170 of 170 transactions
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: